Human communication

Microbot Medical obtains additional patent for LIBERTY®


HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) – Microbot Medical Inc. (Nasdaq: MBOT), has announced that the United States Patent and Commercial Office (USPTO) has issued a notice of authorization for a second request for patent covering the FREEDOM of the Company® Robotic system. Globally, the Company now has 46 issued / authorized patents and 24 pending patent applications and continually submits applications to protect its intellectual property.

“We believe the United States is the biggest and most important market opportunity for LIBERTY® Robotic System, and with two allocations in just a few months, it clearly demonstrates the innovative nature of our technology, ”commented Harel Gadot, CEO, Chairman and Chairman of the Board. “2022 promises to be an important year for LIBERTY® Robotic system. It is essential that we approach this period knowing that we have safeguards in place, so that we can ultimately monetize our intellectual property, reap potential business opportunities, and maximize shareholder value.

The authorized claims cover a modular robotic system for handling at least two elongated and flexible surgical tools, the system comprising at least one unit operable to move a first tool and a base operable to move a second tool, wherein the base serves. mounting bracket for the units, and each unit communicates with the base in one of mechanical coupling, power supply, and data communication.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in transformational micro-robotic technologies, focusing primarily on the natural and artificial lights of the human body. Microbot’s current proprietary technology platforms form the basis for the development of a Multi-Generation Pipeline (MGPP) portfolio.

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham and Yossi Bornstein with the aim of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. More information about Microbot Medical is available at http://www.microbotmedical.com.

Safe harbor

Statements relating to the recorded direct offering, timing, amount and intended use of the products and statements relating to future financial and / or operating results, future growth of research, technology, development clinical and potential opportunities for Microbot Medical Inc. and its subsidiaries, as well as other statements concerning the expectations, beliefs, objectives, plans or future prospects expressed by the management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and federal securities laws. All statements that are not historical facts (including, but not limited to, statements that contain words such as “will”, “believes”, “plans”, “anticipates”, “expects” “And” estimates “) should also be considered as forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and / or commercialization of potential products, including LIBERTY and SCS, the result of its studies to assess LIBERTY, SCS and other existing and future technologies, uncertainty in the results of preclinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to raise future capital; and protection and maintenance of intellectual property rights. Additional information on the risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the website of the SEC at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contact:

Michel Polyviou
EVC Group
[email protected]
732-933-2754